Week in Review: Roche Seeks China Partners with First-in-Class, Best-in-Class Products

Roche is seeking China partners that are developing innovative drugs with unique differentiators -- first-in-class or best-in-class -- according to Dr. Darren Ji in an exclusive ChinaBio® Today interview; WuXi PharmaTech is collaborating with Foundation Medicine to identify target populations for cancer drug trials using the FoundationOne® assay, a test for genetic abnormalities associated with cancer; Fosun Pharma led a $12 million fundraising in Check-Cap, an Israeli medical device company developing an ingestible endoscopic capsule; China Materialia of Shanghai led a $5.7 million Series C financing for ZipLine Medical of California, which makes novel noninvasive surgical skin closure products; Enigma Diagnostics of England and Beijing Leadman Biochemistry will develop Enigma's molecular diagnostic PoC infectious disease test in China; Akers Biosciences of New Jersey and Hainan Savy Investment Management will undertake China development of Akers' rapid diagnostic screening and testing products; Powertech Technology, a distributor of laboratory tools based in Xiamen, signed a three-year agreement for China distribution of Pressure BioSciences' pressure-based lab tools; CardioKinetix of California enrolled the first ten patients in a China clinical trial of its first-in-class, minimally invasive medical device to treat heart failure; and TWi Pharma of Taiwan was granted Orphan Drug designation in the US for the use of its lead drug to treat a rare genetic skin disease, epidermolysis bullosa. More details.... Stock Symbols: (VX: ROG) (NYSE: WX) (NSDQ: FMI) (SHA: 600196; HK: 2196) (SHE: 300289) (NSDQ: AKER; LSE: AKR) (OTCQB: PBIO) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.